Pliant Therapeutics PLRX 深 沪
已收盘 10-02 16:00:00 美东时间
1.035
-0.015
-1.43%
华盛通- 最 高1.065
- 今 开1.06
- 成交量 40.28万股
- 最 低 1.03
- 昨 收 1.05
- 总市值 6408.92万
- 52周最高 1.95
- 市盈率 静 --
- 换手率 0.65%
- 52周最低 1.02
- 委 比 73.23%
- 总股本 6192.19万
- 历史最高 43.92
- 量 比 1.23
- 振 幅 3.33%
- 历史最低 1.02
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Pliant Therapeutics appoints David Raben, M.D., as Chief Medical Officer. With over 30 years of oncology expertise, Raben brings significant experience in drug development and clinical trials. His leadership is expected to advance the company's PLN-101095 program, a targeted therapy for solid tumors. Raben previously led clinical development at Bicara Therapeutics and held key roles at Amgen and Genentech, focusing on innovative cancer treatments...
09-30 20:10
Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors
Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins, in combination with pembrolizumab for the potential the treatme...
08-18 20:35
Pliant Therapeutics Q2 EPS $(0.36) Misses $(0.34) Estimate
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 49.3 percent increase over losses of $(0.71) per share from the same period last year.
08-12 04:21
Pliant Therapeutics Announces Dosing Of First Participant In FORTIFY Phase 1b Open-Label Indication Expansion Clinical Trial Of PLN-101095 In Combination With Pembrolizumab, In Patients With ICI-Refractory Advanced Or Metastatic Solid Tumors
Pliant Therapeutics (NASDAQ:PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients
04-30 20:33
Pliant Therapeutics Announces Board Retirements and Option Repricing
Pliant Therapeutics ( ($PLRX) ) just unveiled an announcement. Pliant Therapeut...
04-18 05:33
Pliant Therapeutics Launches New $50 Million ATM Program
The latest announcement is out from Pliant Therapeutics ( ($PLRX) ). On March 3...
03-31 06:54
Pliant Therapeutics Presents Data From Phase 1 Trial Of PLN-101095 At AACR Annual Meeting 2026
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of
03-18 21:03
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics announced the oral presentation of Phase 1 data for PLN-101095 at the AACR Annual Meeting in San Diego. The presentation, titled "First-in-human phase I study of PLN-101095," will be held on April 18, 2026, at 10:21 a.m. PT in Ballroom 6A. PLN-101095 is a dual αvβ8/αvβ1 integrin inhibitor designed to overcome immune checkpoint resistance by targeting TGF-β activation in the tumor microenvironment. The Phase 1 trial evaluates i...
03-18 13:00
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
